

This listing of the claims will replace all prior versions and listings of claims in the application:

**Listing of the Claims:**

1. (Cancelled).

2. (Previously Presented) A method of reducing the level of C-reactive protein (CRP) in an individual subject to a CRP associated inflammatory condition, comprising administering to the individual an effective amount of a composition comprising 3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid.

Claims 3-5 (Cancelled).

6. (Currently Amended) A method of reducing the level of an inflammatory marker in an individual subject to end-stage renal disease comprising administering to the individual a composition comprising ~~the compound of claim 2~~ 3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid in an effective amount.

7. (Original) The method of claim 6, wherein said inflammatory marker is C-reactive protein (CRP).

Claims 8-10 (Cancelled).

11. (Currently Amended) A method for ameliorating a symptom of an inflammatory condition in an individual subject to an inflammatory condition comprising administering to the individual [the] a composition comprising a compound of claim 2 3-(6-Hydroxy-2,7,8-trimethyl-chroman-2-yl)-propionic acid, in an amount effective to reduce the level of an inflammatory marker associated with said inflammatory condition.

12. (Original) The method of claim 11, wherein said inflammatory marker is C-reactive protein (CRP).

13. (Original) The method of claim 11, wherein said inflammatory condition is selected from the group consisting of cardiovascular inflammatory condition, respiratory inflammatory condition, sepsis, diabetes, muscle fatigue, systemic lupus erythematosus (SLE), end stage renal disease (ESRD), premenstrual syndrome (PMS), and periodontal disease.

Claims 14-17 (Cancelled).

18. (Previously Presented) The method of claim 11, wherein said inflammatory marker is C-reactive protein (CRP) or IL-6.

19. (Cancelled).

20. (Previously presented) The method of claim 2, wherein said composition further comprises a pharmaceutically acceptable carrier.

Claims 21-22 (Cancelled).